Form 4: Cytokinetics CEO Robert Blum Executes Stock Options and Sells Shares
SEC Form 4
Cytokinetics' CEO, Robert Blum, exercised stock options and sold a portion of the acquired shares on September 30, 2024.
Summary
- On September 30, 2024, Robert I. Blum, the President and CEO of Cytokinetics Inc., executed non-qualified stock options to acquire 5,000 shares of common stock at a price of $6.67 per share.
- Simultaneously, Mr. Blum sold 5,000 shares of common stock at a price of $52.14 per share.
- Following these transactions, Mr. Blum directly owns 397,456 shares of Cytokinetics common stock.
- He also indirectly owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.
- Mr. Blum also holds 74,727 non-qualified stock options.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This is a routine disclosure of insider trading activity, which is common for executives of publicly traded companies. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 03/23/2016 | Date exercisable for non-qualified stock option. |
| 02/23/2026 | Expiration date for non-qualified stock option. |
| 09/30/2024 | Date of transaction: exercise of stock options and sale of shares. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.